Blood samples will be collected at different times.
Blood samples will be collected at different times.: For patients with localized leiomyosarcoma, samples will be collected:
* At Baseline.
* Before surgery (for patients who have had neoadjuvant treatment (external radiotherapy and/or chemotherapy)).
* After surgery.
* At each control visit.
* At local or metastatic recurrence (or at 24 months post inclusion if no progression).
For patients with metastatic leiomyosarcoma, samples will be collected:
* At Baseline.
* At each therapeutic line.
* At progression (or at 24 months post inclusion if no progression).
Study summary
Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood and the evolution of this rate over time.
The study will be conducted on a population of patients with leiomyosarcoma and treated in the context of routine care. 20 patients will be included:
* 10 patients with localized disease.
* 10 patients with metastatic disease.
For each included patient, blood samples will be collected during baseline visit and up to 24 months after inclusion.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Patient with leiomyosarcoma.
2. Diagnosis of sarcoma histologically confirmed by the RRePS network (Réseau de Référence en Pathologie des Sarcomes et des Viscères)
3. Localized or metastatic disease
4. Newly diagnosed patient who has not yet initiated specific treatment for sarcoma
5. Age ≥ 18 years
6. Patient affiliated to a Social Security system in France.
7. Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedures
Exclusion Criteria:
1. Diagnosis of any other histological subtype of soft tissue sarcoma
2. Associated pathology(ies) that may interfere with the study procedure
3. Pregnant or breastfeeding woman
4. Any psychological, family, geographical or sociological condition that does not allow for compliance with the medical follow-up and/or procedures provided for in the study protocol.
5. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Primary outcome measure(s)
The longitudinal evolution of rate of patients with "cancer cell / macrophage" hybrid cells in peripheral blood. — 24 months after the end of inclusions.
Trial sites (1)
Facility
City
Region
Status
Institut Universitaire du Cancer Toulouse - Oncopole
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.